The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Ele...

Full description

Saved in:
Bibliographic Details
Main Authors: Fruchart, Jean-Charles, Santos, Raul D., Aguilar-Salinas, Carlos, Aikawa, Masanori, Kodama, Tatsuhiko, Rasadi, Khalid Al, Amarenco, Pierre, Barter, Philip J., Ceska, Richard, Corsini, Alberto, Després, Jean-Pierre, Duriez, Patrick, Eckel, Robert H., Ezhov, Marat V., Farnier, Michel, Ginsberg, Henry N., Hermans, Michel P., Ishibashi, Shun, Karpe, Fredrik, Koenig, Wolfgang, Krempf, Michel, Lim, Soo, Lorenzatti, Alberto J., McPherson, Ruth, Nuñez-Cortes, Jesus Millan, Nordestgaard, Børge G., Ogawa, Hisao, Packard, Chris J., Plutzky, Jorge, Ponte-Negretti, Carlos I., Pradhan, Aruna, Ray, Kausik K., Reiner, Željko, Ridker, Paul M., Ruscica, Massimiliano, Sadikot, Shaukat, Shimano, Hitoshi, Sritara, Piyamitr, Stock, Jane K., Su, Ta-Chen, Susekov, Andrey V., Tartar, André, Taskinen, Marja-Riitta, Tenenbaum, Alexander, Tokgözoğlu, Lale S., Tomlinson, Brian, Tybjærg-Hansen, Anne, Valensi, Paul, Vrablík, Michal, Wahli, Walter, Watts, Gerald F., Yamashita, Shizuya, Yokote, Koutaro, Zambon, Alberto, Libby, Peter
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2019
Subjects:
Online Access:https://hdl.handle.net/10356/87826
http://hdl.handle.net/10220/49307
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-87826
record_format dspace
spelling sg-ntu-dr.10356-878262020-11-01T05:30:07Z The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential Fruchart, Jean-Charles Santos, Raul D. Aguilar-Salinas, Carlos Aikawa, Masanori Kodama, Tatsuhiko Rasadi, Khalid Al Amarenco, Pierre Barter, Philip J. Ceska, Richard Corsini, Alberto Després, Jean-Pierre Duriez, Patrick Eckel, Robert H. Ezhov, Marat V. Farnier, Michel Ginsberg, Henry N. Hermans, Michel P. Ishibashi, Shun Karpe, Fredrik Koenig, Wolfgang Krempf, Michel Lim, Soo Lorenzatti, Alberto J. McPherson, Ruth Nuñez-Cortes, Jesus Millan Nordestgaard, Børge G. Ogawa, Hisao Packard, Chris J. Plutzky, Jorge Ponte-Negretti, Carlos I. Pradhan, Aruna Ray, Kausik K. Reiner, Željko Ridker, Paul M. Ruscica, Massimiliano Sadikot, Shaukat Shimano, Hitoshi Sritara, Piyamitr Stock, Jane K. Su, Ta-Chen Susekov, Andrey V. Tartar, André Taskinen, Marja-Riitta Tenenbaum, Alexander Tokgözoğlu, Lale S. Tomlinson, Brian Tybjærg-Hansen, Anne Valensi, Paul Vrablík, Michal Wahli, Walter Watts, Gerald F. Yamashita, Shizuya Yokote, Koutaro Zambon, Alberto Libby, Peter Lee Kong Chian School of Medicine (LKCMedicine) Residual Cardiovascular Risk Visceral Obesity Science::Medicine In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk. Published version 2019-07-11T09:17:34Z 2019-12-06T16:50:16Z 2019-07-11T09:17:34Z 2019-12-06T16:50:16Z 2019 Journal Article Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Rasadi, K. A., Amarenco, P., . . . Libby, P. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential. Cardiovascular Diabetology, 18(1), 71-. doi:10.1186/s12933-019-0864-7 https://hdl.handle.net/10356/87826 http://hdl.handle.net/10220/49307 10.1186/s12933-019-0864-7 en Cardiovascular Diabetology © 2019 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. 20 p. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Residual Cardiovascular Risk
Visceral Obesity
Science::Medicine
spellingShingle Residual Cardiovascular Risk
Visceral Obesity
Science::Medicine
Fruchart, Jean-Charles
Santos, Raul D.
Aguilar-Salinas, Carlos
Aikawa, Masanori
Kodama, Tatsuhiko
Rasadi, Khalid Al
Amarenco, Pierre
Barter, Philip J.
Ceska, Richard
Corsini, Alberto
Després, Jean-Pierre
Duriez, Patrick
Eckel, Robert H.
Ezhov, Marat V.
Farnier, Michel
Ginsberg, Henry N.
Hermans, Michel P.
Ishibashi, Shun
Karpe, Fredrik
Koenig, Wolfgang
Krempf, Michel
Lim, Soo
Lorenzatti, Alberto J.
McPherson, Ruth
Nuñez-Cortes, Jesus Millan
Nordestgaard, Børge G.
Ogawa, Hisao
Packard, Chris J.
Plutzky, Jorge
Ponte-Negretti, Carlos I.
Pradhan, Aruna
Ray, Kausik K.
Reiner, Željko
Ridker, Paul M.
Ruscica, Massimiliano
Sadikot, Shaukat
Shimano, Hitoshi
Sritara, Piyamitr
Stock, Jane K.
Su, Ta-Chen
Susekov, Andrey V.
Tartar, André
Taskinen, Marja-Riitta
Tenenbaum, Alexander
Tokgözoğlu, Lale S.
Tomlinson, Brian
Tybjærg-Hansen, Anne
Valensi, Paul
Vrablík, Michal
Wahli, Walter
Watts, Gerald F.
Yamashita, Shizuya
Yokote, Koutaro
Zambon, Alberto
Libby, Peter
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
description In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Fruchart, Jean-Charles
Santos, Raul D.
Aguilar-Salinas, Carlos
Aikawa, Masanori
Kodama, Tatsuhiko
Rasadi, Khalid Al
Amarenco, Pierre
Barter, Philip J.
Ceska, Richard
Corsini, Alberto
Després, Jean-Pierre
Duriez, Patrick
Eckel, Robert H.
Ezhov, Marat V.
Farnier, Michel
Ginsberg, Henry N.
Hermans, Michel P.
Ishibashi, Shun
Karpe, Fredrik
Koenig, Wolfgang
Krempf, Michel
Lim, Soo
Lorenzatti, Alberto J.
McPherson, Ruth
Nuñez-Cortes, Jesus Millan
Nordestgaard, Børge G.
Ogawa, Hisao
Packard, Chris J.
Plutzky, Jorge
Ponte-Negretti, Carlos I.
Pradhan, Aruna
Ray, Kausik K.
Reiner, Željko
Ridker, Paul M.
Ruscica, Massimiliano
Sadikot, Shaukat
Shimano, Hitoshi
Sritara, Piyamitr
Stock, Jane K.
Su, Ta-Chen
Susekov, Andrey V.
Tartar, André
Taskinen, Marja-Riitta
Tenenbaum, Alexander
Tokgözoğlu, Lale S.
Tomlinson, Brian
Tybjærg-Hansen, Anne
Valensi, Paul
Vrablík, Michal
Wahli, Walter
Watts, Gerald F.
Yamashita, Shizuya
Yokote, Koutaro
Zambon, Alberto
Libby, Peter
format Article
author Fruchart, Jean-Charles
Santos, Raul D.
Aguilar-Salinas, Carlos
Aikawa, Masanori
Kodama, Tatsuhiko
Rasadi, Khalid Al
Amarenco, Pierre
Barter, Philip J.
Ceska, Richard
Corsini, Alberto
Després, Jean-Pierre
Duriez, Patrick
Eckel, Robert H.
Ezhov, Marat V.
Farnier, Michel
Ginsberg, Henry N.
Hermans, Michel P.
Ishibashi, Shun
Karpe, Fredrik
Koenig, Wolfgang
Krempf, Michel
Lim, Soo
Lorenzatti, Alberto J.
McPherson, Ruth
Nuñez-Cortes, Jesus Millan
Nordestgaard, Børge G.
Ogawa, Hisao
Packard, Chris J.
Plutzky, Jorge
Ponte-Negretti, Carlos I.
Pradhan, Aruna
Ray, Kausik K.
Reiner, Željko
Ridker, Paul M.
Ruscica, Massimiliano
Sadikot, Shaukat
Shimano, Hitoshi
Sritara, Piyamitr
Stock, Jane K.
Su, Ta-Chen
Susekov, Andrey V.
Tartar, André
Taskinen, Marja-Riitta
Tenenbaum, Alexander
Tokgözoğlu, Lale S.
Tomlinson, Brian
Tybjærg-Hansen, Anne
Valensi, Paul
Vrablík, Michal
Wahli, Walter
Watts, Gerald F.
Yamashita, Shizuya
Yokote, Koutaro
Zambon, Alberto
Libby, Peter
author_sort Fruchart, Jean-Charles
title The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
title_short The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
title_full The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
title_fullStr The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
title_full_unstemmed The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
title_sort selective peroxisome proliferator-activated receptor alpha modulator (spparmα) paradigm : conceptual framework and therapeutic potential
publishDate 2019
url https://hdl.handle.net/10356/87826
http://hdl.handle.net/10220/49307
_version_ 1683494411993874432